DIGITAL TELOMERE / VOL. I / NO. 4
— i —
¶ a folio in four gatherings

 

The molecular clock has been audited. The ledger is uneven. Below, the marginalia keep an honest account.

— ii —
gathering I

THE PREMISE

Let it be conceded, before the lights are turned up, that we are not here to celebrate. The chromosome ends, and at the ends of the chromosome there are caps, and at the caps there is a small, careful arithmetic in which something is subtracted each time the cell deigns to copy itself. The arithmetic is not a metaphor. The arithmetic is the thing.

What is forbidden in scholarship—and therefore necessary—is to admit that the discovery has been thoroughly purchased. The cap-and-shorten apparatus, named in the textbooks for two women who were paid in patience and citations, has since been rented out to firms whose annual reports list mortality as an addressable market. i.

We are not those firms. We are an editorial body, anonymous by preference, and we have spent four hundred and thirteen evenings reading what the firms publish and what they do not.

A telomere, properly described, is a refusal. It refuses to let the chromosome be confused with its neighbour. It refuses to be ground down without warning. It refuses, finally and elegantly, to lie about how many copies remain.

What follows is a short audit. It contains nothing proprietary, because we own nothing; nothing classified, because we have no clearances; and nothing, in particular, that any of the firms would prefer you to read at this hour. q.v.

¶ continued in gathering II
— iii —
gathering II

THE EVIDENCE

The evidence is not photographable. It accumulates the way a lake collects strangers' breath: unevenly, without ceremony, and only the careful patron knows it has happened.

The shortening rate, when honestly measured in primary fibroblasts of healthy adult donors, is fifty to one hundred base pairs per division — a quantity small enough to flatter a press release and large enough to end a life on schedule.

Across the literature one finds a recurring courtesy: the figure is reported, the implication is omitted. The implication is that the cell counts, and the cell is, in this respect, a more honest accountant than any of the firms now licensing its dignity. ii.

Telomerase, the enzyme that may extend the cap, is held in reserve by most somatic cells the way a small village holds a defibrillator: it exists, it is locked, and the key is given out only to the line of cells that are immortal in principle and dangerous in practice.

To prescribe immortality, one must therefore prescribe a kind of controlled tumour. This is the sentence the firms would prefer to phrase another way, and have. The phrasings they have purchased run, at present, to four hundred and seventeen pages of marketing copy and a single peer-reviewed retraction.

A reasonable scholar concludes: the molecular clock cannot be stopped without unstopping the brake on growth, and the brake on growth is what distinguishes a long life from a brief catastrophe.

The reasonable scholar, of course, is not invited to the launch.

— iv —
gathering III

THE DISSENT

What we have learned, after the fourth hundredth evening, is that the disagreement is not scientific. The science is, in fact, gracious: it admits its own ceiling. The disagreement is editorial.

The clinical pipeline conclusively demonstrates a safe and durable extension of healthy human lifespan. the clinical pipeline has, more honestly, demonstrated that healthy people will pay to be told they are running out.

We do not write to embarrass the firms. They are quite capable of that themselves, and have been, in nine quarterly filings since the spring of last year. cf.

We write because the molecular clock is, properly understood, a beautiful instrument. It keeps time the way an old church keeps weather: badly, locally, and with affection. To replace it with a metered subscription is not progress. It is a small, well-funded vandalism.

The page tilts, here, deliberately. Read it as a bookbinder pressing too hard.

What remains, after the marketing copy is set aside, is a short list of legitimate questions. We will not list them here. We will leave them in the rail beneath your reading, where the honest sentences live, and where you may collect them in your own time.

— v —
§ final

COLOPHON

Set in JetBrains Mono and Cormorant Garamond on a parchment field at 17px. Pull-quotes in Space Mono. Marginalia in Caveat, graphite blue.

Composed without a sponsor and without an investor letter. Distributed by means we do not control, in a year we cannot predict.

The chrome dot, the only persistent affordance on this page, will now stop pulsing. The reader is released.

DIGITAL TELOMERE · VOL. I · NO. 4 · MMXXVI

¶ end of folio